News

These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More
On Monday, nine-session winning streaks ended for both the S&P 500 and Dow Jones Industrial Average.These stocks were poised ...
Fierce Healthcare13h
Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
24/7 Wall St. on MSN9h
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers short interest at critical levels after best weekly gain: report
Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.
Modern Healthcare21h
Hims & Hers names Amazon exec as chief of operations
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Investor's Business Daily on MSN17h
Hims & Hers Names New COO. Stock Rallies.
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer.